Compare VENUS REMEDIES with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs DIVIS LABORATORIES - Comparison Results

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES DIVIS LABORATORIES VENUS REMEDIES/
DIVIS LABORATORIES
 
P/E (TTM) x -1.4 34.7 - View Chart
P/BV x 0.1 6.7 1.5% View Chart
Dividend Yield % 0.0 0.9 -  

Financials

 VENUS REMEDIES   DIVIS LABORATORIES
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
DIVIS LABORATORIES
Mar-19
VENUS REMEDIES/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1261,639 7.7%   
Low Rs611,115 5.5%   
Sales per share (Unadj.) Rs301.8186.3 162.0%  
Earnings per share (Unadj.) Rs-24.951.0 -48.8%  
Cash flow per share (Unadj.) Rs2.557.3 4.4%  
Dividends per share (Unadj.) Rs016.00 0.0%  
Dividend yield (eoy) %01.2 0.0%  
Book value per share (Unadj.) Rs293.3261.8 112.0%  
Shares outstanding (eoy) m12.34265.47 4.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.37.4 4.2%   
Avg P/E ratio x-3.827.0 -13.9%  
P/CF ratio (eoy) x36.724.0 152.9%  
Price / Book Value ratio x0.35.3 6.1%  
Dividend payout %031.4 0.0%   
Avg Mkt Cap Rs m1,154365,592 0.3%   
No. of employees `0000.911.8 7.8%   
Total wages/salary Rs m3935,423 7.2%   
Avg. sales/employee Rs Th4,026.14,175.1 96.4%   
Avg. wages/employee Rs Th425.0457.7 92.8%   
Avg. net profit/employee Rs Th-331.81,141.8 -29.1%   
INCOME DATA
Net Sales Rs m3,72449,463 7.5%  
Other income Rs m231,556 1.4%   
Total revenues Rs m3,74751,019 7.3%   
Gross profit Rs m39518,718 2.1%  
Depreciation Rs m3381,689 20.0%   
Interest Rs m35435 1,012.3%   
Profit before tax Rs m-27518,551 -1.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m325,023 0.6%   
Profit after tax Rs m-30713,527 -2.3%  
Gross profit margin %10.637.8 28.0%  
Effective tax rate %-11.527.1 -42.4%   
Net profit margin %-8.227.3 -30.1%  
BALANCE SHEET DATA
Current assets Rs m2,63846,501 5.7%   
Current liabilities Rs m2,3058,468 27.2%   
Net working cap to sales %8.976.9 11.6%  
Current ratio x1.15.5 20.8%  
Inventory Days Days135131 103.5%  
Debtors Days Days4686 54.0%  
Net fixed assets Rs m4,87125,797 18.9%   
Share capital Rs m123531 23.2%   
"Free" reserves Rs m3,49668,962 5.1%   
Net worth Rs m3,61969,493 5.2%   
Long term debt Rs m1,3740-   
Total assets Rs m7,50980,383 9.3%  
Interest coverage x0.2531.0 0.0%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.50.6 80.6%   
Return on assets %0.616.9 3.7%  
Return on equity %-8.519.5 -43.6%  
Return on capital %1.626.7 5.9%  
Exports to sales %00-   
Imports to sales %13.924.6 56.3%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m51712,187 4.2%   
Fx inflow Rs m041,238 0.0%   
Fx outflow Rs m51712,405 4.2%   
Net fx Rs m-51728,833 -1.8%   
CASH FLOW
From Operations Rs m5149,543 5.4%  
From Investments Rs m-123-6,854 1.8%  
From Financial Activity Rs m-387-2,459 15.7%  
Net Cashflow Rs m4230 1.8%  

Share Holding

Indian Promoters % 32.9 52.0 63.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 11.8 1.5%  
FIIs % 0.6 19.0 3.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 17.2 386.0%  
Shareholders   20,121 31,796 63.3%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   DR. REDDYS LAB  IPCA LABS  ASTRAZENECA PHARMA  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  

Compare VENUS REMEDIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 334 Points Lower; IT and Telecom Stocks Witness Huge Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their day deep in the red. At the closing bell, the BSE Sensex stood lower by 334 points (down 0.9%).

Related Views on News

DR. LAL PATHLABS LTD at All Time High; BSE HEALTHCARE Index Up 1.7% (Market Updates)

Oct 22, 2019 | Updated on Oct 22, 2019

DR. LAL PATHLABS LTD share price has hit an all time high at Rs 1,550 (up 4.5%). The BSE HEALTHCARE Index is up by 1.7%. Among the top gainers in the BSE HEALTHCARE Index today are DR. LAL PATHLABS LTD (up 4.5%) and PFIZER (up 1.5%). The top losers include SANOFI INDIA and ABBOTT INDIA .

DIVIS LABORATORIES 2018-19 Annual Report Analysis (Annual Result Update)

Oct 10, 2019 | Updated on Oct 10, 2019

Here's an analysis of the annual report of DIVIS LABORATORIES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

DIVIS LABORATORIES Announces Quarterly Results (1QFY20); Net Profit Up 0.4% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.4% YoY). Sales on the other hand came in at Rs 11 bn (up 14.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY19); Net Profit Up 10.6% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 10.6% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Oct 22, 2019 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS